Perimenopause Rare and Atypical Presentations: What Clinicians and Patients Often Miss

Perimenopause is the hormonal transition that precedes menopause, marked by irregular ovulation and increasingly erratic estradiol and progesterone levels, typically starting in a woman's mid-to-late 40s and lasting several years until 12 months after the final menstrual period. Most patient education focuses on hot flashes, night sweats, and cycle changes. A meaningful minority of women instead present first with symptoms that look neurological, psychiatric, cardiac, or otologic, and these presentations are frequently worked up and treated as standalone diagnoses without anyone ever checking whether hormonal transition is the underlying driver.

The core clinical point of this article is narrow but useful: when a woman in her mid-40s to mid-50s develops a new, otherwise-unexplained symptom in a neurological, psychiatric, autonomic, or sensory system, hormonal status belongs in the initial differential, not as a diagnosis of exclusion reached after months of specialist referrals. This is a clinical judgment supported by mechanistic plausibility and observational patterns, not a proven cause-and-effect chain for every symptom below, and readers should not conclude that hormone therapy is an established treatment for most of these atypical presentations.

Why these presentations get missed

During perimenopause, estradiol does not decline in a smooth line. Levels can swing between premenopausal-range surges and sharp drops within the same month, and progesterone typically falls earlier and more steeply than estrogen. Random blood draws can look "normal" even while a woman is experiencing withdrawal-type symptoms between surges, which is one reason single-point hormone testing is a poor screening tool on its own. The Endocrine Society and the North American Menopause Society (NAMS) have both cautioned against using a single FSH value to rule perimenopause in or out; serial testing and clinical history (especially cycle-length variability of 7 or more days, per the STRAW+10 staging criteria) carry more weight than one lab value.

Diagnostic anchoring compounds the problem. Once a clinician lands on a primary diagnosis, such as depression, epilepsy, or an autoimmune process, there is often no return visit to ask whether the hormonal transition itself could explain the picture. Observational cohorts, most notably the Study of Women's Health Across the Nation (SWAN), have tracked mood, cognition, and musculoskeletal symptoms through the transition and consistently find that symptom burden rises during late perimenopause and falls after menopause, a pattern more consistent with a hormonal driver than with permanent disease. Exact effect sizes from SWAN and similar cohorts vary by outcome and publication; readers and clinicians who want a specific number for their own decision-making should pull the original paper rather than rely on any single quoted statistic, including ones on this page.

Neurological presentations

Seizures. Estrogen has pro-excitatory effects on neuronal membranes, while the progesterone metabolite allopregnanolone acts on GABA-A receptors and is anti-convulsant. Because progesterone tends to fall faster than estrogen early in perimenopause, seizure threshold can drop. Women with pre-existing epilepsy commonly report perimenopausal worsening, a pattern long described in the epilepsy literature as related to "catamenial" hormonal sensitivity. New-onset seizures without any prior history are much less common, but any woman aged roughly 45 to 55 with a first unprovoked seizure should still receive standard neurological work-up (imaging, EEG) rather than an assumption that hormones alone explain it; hormonal testing can be added as supportive context, not a substitute for ruling out structural or metabolic causes.

Cognitive complaints ("brain fog"). The perimenopausal pattern is usually slowed processing speed and verbal memory lapses rather than the progressive executive-function decline seen in dementia, and cohort data suggest these complaints often ease after the transition completes. That said, a normal-appearing "brain fog" story in an older patient, or one with progressive worsening rather than fluctuation, still deserves a standard cognitive work-up; perimenopause should narrow the differential, not close it.

Headache. Migraine, especially migraine with aura, is common in reproductive-age women, and hormonal swings during perimenopause can transform previously episodic migraine into a more frequent, harder-to-treat pattern for some women, with improvement often reported after the transition ends. This is a recognized clinical pattern rather than something with a single definitive mechanism, and standard headache red flags (thunderclap onset, new neurological deficit, papilledema) always require urgent evaluation regardless of menopausal status.

Psychiatric presentations

Depression. A first depressive episode with no prior psychiatric history, arising in the perimenopausal age window, is a recognized clinical entity distinct from depression tied to a life stressor, and cohort studies (including the Harvard Study of Moods and Cycles and SWAN) have reported elevated new-onset depression risk during this transition compared with the premenopausal years. Estrogen modulates serotonergic and dopaminergic signaling, which is the proposed mechanism, though the exact contribution of hormones versus co-occurring sleep disruption, vasomotor symptoms, and life-stage stressors is not fully separated in the literature. NAMS's 2022 position statement on hormone therapy describes estrogen as a reasonable treatment option for perimenopausal depression in appropriate candidates, particularly when vasomotor symptoms are also present, though it does not position hormone therapy as a universal replacement for antidepressants, and readers should check the original 2022 statement rather than rely on a paraphrase for the exact wording of any treatment recommendation.

Psychosis. First-episode psychosis with no prior psychiatric history, occurring in a woman in her mid-40s to early 50s, has been described in small case series, with some patients improving on estradiol therapy alongside standard psychiatric treatment. This is case-level evidence, not a controlled trial finding, and it does not mean estrogen should replace antipsychotic treatment during an acute episode. It does support checking FSH, LH, and estradiol as part of the broader medical work-up for new-onset psychosis in this age group, alongside the standard organic-cause screen (thyroid, autoimmune, substance-related, structural brain imaging).

Anxiety and panic symptoms. New panic-type symptoms in this age window are sometimes misattributed to cardiac or thyroid disease before anyone considers the hormonal transition. Estrogen has documented effects on amygdala reactivity and cortisol response, which offers biological plausibility, but as with depression, disentangling hormonal effects from sleep disruption and vasomotor symptoms in existing studies is difficult, and any new palpitation-associated anxiety symptom still warrants a cardiac and thyroid screen before being attributed to perimenopause alone.

Autonomic and cardiovascular presentations

Estrogen supports vascular tone partly through nitric oxide signaling and baroreflex sensitivity, and its fluctuation during perimenopause has been proposed as a contributing factor in orthostatic intolerance, palpitations on standing, and lightheadedness that can resemble postural orthostatic tachycardia syndrome (POTS). This is a plausible mechanism with growing clinical recognition rather than an established causal pathway, and a POTS-consistent presentation still requires standard tilt-table or autonomic testing; hormonal evaluation is a reasonable addition for women whose symptoms began in the perimenopausal window, not a substitute for the standard work-up.

Palpitations without a documented arrhythmia are also commonly reported in this age group, and a normal Holter monitor or echocardiogram does not mean the symptom is fabricated; a real symptom without a demonstrable rhythm abnormality is a recognized clinical pattern.

New cardiac-type symptoms in midlife women deserve one further caution: chest pain and even acute coronary syndrome (ACS) can have causes unrelated to atherosclerotic disease or hormones, including medication effects. A published case report describes misoprostol-induced acute coronary syndrome in a premenopausal woman, illustrating that reversible, drug-related causes of ACS-like chest pain exist in this age group and must be excluded before any chest symptom is filed under "perimenopause" (case report, 2018). This is a single case report and does not establish that misoprostol-associated ACS is common; it is cited here only to support the general point that new cardiac symptoms in midlife women need a full standard cardiac differential, not a hormonal one by default.

Sensory presentations

Tinnitus and hearing changes. Estrogen receptors are present in cochlear hair cells and the auditory cortex, and observational studies have reported associations between earlier natural menopause and higher rates of self-reported hearing difficulty. This is population-level association data, not proof that hormone therapy reverses hearing loss, and new hearing symptoms still warrant standard audiology and ENT evaluation; a hormonal question can be layered on top of, not instead of, that work-up.

Burning mouth syndrome. This is chronic oral burning without visible mucosal disease, occurs far more often in women than men, and peaks in midlife. Case-control data have linked onset to the perimenopausal-to-postmenopausal window, with estrogen receptors present in oral mucosa offering a plausible mechanism. Diagnosis still requires ruling out nutritional deficiencies, oral candidiasis, and other identifiable causes before attributing the symptom to hormones.

Dizziness and vertigo. Balance complaints are common during this transition. Estrogen affects endolymph composition in the inner ear, and some prospective data suggest treated postmenopausal women have lower rates of recurrent benign paroxysmal positional vertigo (BPPV) than untreated women, though vertigo always deserves its own standard vestibular work-up given the range of other causes (including central neurological ones) that must be excluded first.

Musculoskeletal and skin presentations

Joint pain without inflammatory markers. Arthralgia is common during perimenopause and is sometimes mistaken for early rheumatoid arthritis. Estrogen receptors on chondrocytes and synoviocytes support cartilage and synovial health, and cohort data (again, largely from SWAN) suggest joint pain prevalence rises through late perimenopause. Normal or only mildly elevated inflammatory markers (CRP, ESR, RF, anti-CCP) in this context should raise suspicion for a hormonal contribution, but a full rheumatologic evaluation is still appropriate for any persistent inflammatory-pattern joint pain, since perimenopause and early autoimmune disease can coexist.

Skin and hair changes. Estrogen supports dermal collagen synthesis, and skin biopsy studies have documented meaningful collagen loss in the years around menopause. Perimenopausal women may notice increased skin laxity, new or worsening rosacea, diffuse hair thinning (telogen effluvium, distinct from androgen-pattern hair loss), and nail changes. Each has its own standard dermatological work-up; a hormonal explanation is a contributing factor to consider, not a reason to skip dermatology referral.

Gastrointestinal and mucosal presentations

Estrogen and progesterone receptors are distributed throughout the enteric nervous system, and some research has linked perimenopause to increased bloating, constipation, and GI symptom burden compared with premenopausal controls. New GI symptoms in this age range still warrant standard evaluation (and age-appropriate colorectal cancer screening where indicated) before being filed under "hormonal IBS." Similarly, estrogen supports lacrimal gland function, and dry eye complaints are reported more often in this age group; artificial tears remain a reasonable first step regardless of the underlying hormonal contribution.

A decision framework: when does a new symptom deserve a hormonal work-up?

This framework is meant to guide the conversation, not replace clinical judgment or a standard organ-specific work-up.

Step 1: Screen for red flags that require urgent or standard evaluation regardless of hormonal status. These include a first unprovoked seizure, chest pain, focal neurological deficits, thunderclap headache, sudden hearing loss, or any symptom with progressive rather than fluctuating course. These always get the standard urgent work-up first. Hormonal status is added as context, never used to delay it.

Step 2: Establish reproductive context. Ask about cycle-length variability over the past 12 months. Variability of 7 or more days meets STRAW+10 criteria for early perimenopause. Absence of this history does not rule out perimenopause, since some women have few menstrual clues before other symptoms appear, but its presence strengthens the case for a hormonal work-up.

Step 3: Order a hormonal panel, understanding its limits. FSH, LH, estradiol (early follicular phase if still cycling), and AMH provide supportive information. A single normal FSH does not exclude perimenopause; values fluctuate across the transition, and serial testing across cycles is more informative than one draw.

Step 4: Match symptom timing to cycle phase where possible. Symptoms that reliably worsen in the late luteal phase, or that fluctuate rather than steadily progress, fit better with a hormonal pattern. A brief symptom diary over two to three cycles can reveal this pattern even before formal hormone testing returns.

Step 5: Consider a time-limited therapeutic trial only after standard work-up is complete or reasonably excluded. For women without contraindications, a defined trial of estradiol (transdermal formulations are commonly preferred for cardiovascular and clotting risk reasons) with progestogen if the uterus is intact, can be diagnostically informative if symptoms improve. This is off-label or exploratory for most of the atypical presentations described above, since fezolinetant (approved by the FDA in May 2023) and systemic estradiol are FDA-approved for vasomotor symptoms, not for tinnitus, burning mouth syndrome, or joint pain specifically. A treatment trial for these symptoms should be a shared, informed decision, not an assumption that hormone therapy is proven treatment for the atypical symptom itself.

Step 6: Keep specialists in the loop on hormonal timeline. When neurology, rheumatology, ENT, cardiology, or psychiatry is involved, share the menstrual and symptom timeline so the diagnosis isn't finalized in isolation from hormonal context.

Exceptions and cautions: Women on hormonal contraception, women who have had a hysterectomy without oophorectomy, and women with premature ovarian insufficiency require different hormonal interpretation than the general perimenopausal pattern described here, and this framework should not be applied to those groups without adjustment.

What is established, what is plausible, and what is not established

Established: Perimenopause involves erratic, non-linear estrogen and progesterone fluctuation. Vasomotor symptoms, mood changes, and sleep disruption are well-documented and common. Systemic estradiol, with progestogen when the uterus is intact, is FDA-approved for vasomotor symptom management, and fezolinetant is FDA-approved specifically for that indication.

Plausible but not proven as a treatable, causal relationship: New-onset seizures, first-episode psychosis, POTS-like autonomic symptoms, tinnitus, burning mouth syndrome, and joint pain have all been described in association with the perimenopausal transition, with reasonable biological mechanisms proposed. Evidence for these associations comes mostly from small case series, cross-sectional cohorts, and mechanistic studies rather than large controlled trials designed to test hormone therapy against these specific symptoms.

Not established: That hormone therapy is an effective treatment for any of the atypical presentations in this article as a primary indication. Hormone therapy is approved and evidence-supported for vasomotor symptoms and, in appropriately selected women, for perimenopausal depression; extending that evidence to seizures, psychosis, tinnitus, or joint pain requires the individual studies described above, most of which are small, and none of which should be read as guideline-level proof.

When to seek urgent care

A first seizure, chest pain, sudden severe headache, sudden hearing loss, new focal neurological deficit, or acute psychiatric crisis (including suicidal ideation) always warrants urgent evaluation. These situations should never be delayed while waiting for hormone level results or a therapeutic trial of estradiol.

References

1. Misoprostol-induced Acute Coronary Syndrome in a Premenopausal Woman: A Case Report with Literature Review (2018). https://pubmed.ncbi.nlm.nih.gov/29173181/

This article draws on research from the Stages of Reproductive Aging Workshop (STRAW+10) staging criteria, the Study of Women's Health Across the Nation (SWAN) cohort, the Harvard Study of Moods and Cycles, and the North American Menopause Society's 2022 Hormone Therapy Position Statement. Numeric findings from these sources cited in earlier drafts could not be confirmed against primary literature and are presented descriptively instead. Before publication, an editor with database access should verify and cite the original studies for any specific effect sizes, odds ratios, or percentages derived from these research initiatives.